Nokuthula Msimanga, MD
Hospice and Palliative Medicine · Marietta, GANPI 1104950096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among hospice and palliative medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$749
- AstraZeneca$635
- Novo Nordisk$464
- Pfizer$354
- Sumitomo Pharma America, Inc.$264
- Lilly USA, LLC$263
- plus $640 from 14 others
What the payments were for
- Food & beverage$3,370100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $749 |
| AstraZeneca | 26 | $635 |
| Novo Nordisk | 26 | $464 |
| Pfizer | 19 | $354 |
| Sumitomo Pharma America, Inc. | 14 | $264 |
| Lilly USA, LLC | 17 | $263 |
| GSK | 6 | $132 |
| Exact Sciences | 6 | $93 |
| Eisai Inc. | 3 | $73 |
| Amgen | 3 | $60 |
| Astellas Pharma US Inc | 2 | $49 |
| Merck | 3 | $42 |
| Abbott | 2 | $32 |
| Edwards Lifesciences | 1 | $30 |
| Dynavax Technologies Corporation | 1 | $29 |
| Novartis | 1 | $26 |
| Boehringer Ingelheim | 1 | $23 |
| Axonics, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,370 in reported general payments places this provider in the 95th percentile of 69 hospice and palliative medicine providers in Georgia.
See all hospice and palliative medicine providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 133 | $104,128 |
| EliquisApixaban | 85 | $57,188 |
| OzempicSemaglutide | 50 | $45,575 |
| LinzessLinaclotide | 52 | $35,687 |
| GemtesaVibegron | 73 | $35,211 |
| TrulicityDulaglutide | 32 | $32,522 |
| MyrbetriqMirabegron | 46 | $30,326 |
| XareltoRivaroxaban | 22 | $24,798 |
| WegovySemaglutide | 17 | $22,714 |
| JardianceEmpagliflozin | 12 | $21,574 |
| RybelsusSemaglutide | 14 | $19,307 |
| MounjaroTirzepatide | 15 | $17,291 |
| FarxigaDapagliflozin Propanediol | 18 | $15,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,658 |
| Repatha SureclickEvolocumab | 21 | $13,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $42 | $104,128133 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $464 | $87,59781 claims |
| PfizerEliquis | $354 | $57,18885 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $263 | $49,81347 claims |
| AbbVieLinzess, Synthroid | $749 | $44,638149 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $264 | $35,21173 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $30,32646 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $132 | $22,02134 claims |
| Boehringer IngelheimJardiance | $23 | $21,57412 claims |
| AstraZenecaFarxiga | $635 | $15,97318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hospice and palliative medicine providers in Georgia.
Other hospice and palliative medicine in Marietta
- Michelle ParkMarietta$2K
- Tanya NikolovaMarietta$1K
- Christina ChenMarietta$1K
- Melissa ScheppMarietta$158
- Nikhita AnanthulaMarietta$117
- Catherine TrippeMarietta$75
- Huda SayedMarietta$22
- Veronica SudekumWarner Robins$7K
- Anthony EkwenchiAustell$5K
- Joshua JacksonAtlanta$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.